MOLECULAR VECTORS AND PEPTIDOMICS CORE
MOLECULAR VECTORS AND PEPTIDOMICS CORE
批准号:
7767527
负责人:
NORIYUKI KASAHARA
金额:
$12.12万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-12-01 至 2014-11-30
关键词:
Adenovirus VectorAdvisory ServicesAnimal ModelArtsBiologicalBiological ProcessCell LineCellsChemicalsCodeCommercial SectorsComplementComplexComplex MixturesConsultationsCore FacilityCustomDataDetectionDevelopmentDigestionDigestive System DisordersDisciplineDiseaseDisease MarkerDoseEmbryoEndocrineEnsureEventFaceFamilyFigs - dietaryFunctional RNAFunctional disorderGastrointestinal PhysiologyGastrointestinal tract structureGene DeliveryGene ExpressionGene ProteinsGene TransferGenesGeneticGrowth FactorHealthHepatobiliaryHormonesHuman Genome ProjectImmunologicsIn VitroIndividualInvestigational TherapiesKnowledgeLabelLaboratoriesLibrariesMaintenanceMammalian CellMass Spectrum AnalysisMediatingMethodologyMethodsMolecularMolecular WeightMorphologyNeuropeptidesOocytesOrganogenesisPancreasPathogenesisPatternPeptidesPhysiological ProcessesPhysiologyPlayPopulationPositioning AttributeProcessProductionProductivityProtein AnalysisProtein IsoformsProteinsProteomicsProtocols documentationRNARNA InterferenceRNA SequencesRNA SplicingRadiolabeledReagentRegulationRegulator GenesResearchResearch ActivityResearch PersonnelResearch Project GrantsResolutionResourcesRiskRoleSelection BiasServicesSignal TransductionSomatic CellSourceSystemTechniquesTechnologyTimeTissuesTrainingTransfectionTransgenic AnimalsVariantVendorViral GenesViral VectorWorkabsorptionbaseblastocystcell motilitycellular imagingcellular transductioncostcytokinedesigndesign and constructionexpression vectorflexibilityfunctional genomicsgastrointestinalgastrointestinal systemgene transfer vectorhigh throughput technologyimmortalized cellimprovedin vivoinstrumentinstrumentationinterestmeetingsmolecular massmolecular vectormutantnew therapeutic targetoperationoverexpressionparacrinepolyclonal antibodyprotein expressionradiotracerresearch studyresponsesmall hairpin RNAsynthetic peptidetooltransgene expressionvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The completion of the Human Genome Project comprising approximately 30,000 genes with even more
numerous splice variants generating additional protein coding sequences, and the recent identification of
multiple species of RNA that are now recognized to perform critical regulatory functions through RNA
interference, have provided a wealth of new genetic information. However, with this newly acquired
knowledge, molecular and cellular biologists in all disciplines now face the tremendous task of
understanding the functions of individual genetic sequences and protein isoforms whose significance and
impact on health and disease may be unclear. Even with high-throughput technologies such as microarrays
or proteomics, the gene or protein expression pattern in toto often yields a composite picture in which
primary and secondary effects are difficult to unravel, and ultimately the true biological or pathogenetic
significance of individual candidate cDNAs encoding proteins or non-coding RNA sequences must be
confirmed directly.
The field of gastrointestinal research is certainly no exception, and moreover, represents an even more
complex system in which coordinately regulated genetic and protein expression patterns result in the
development and maintenance of specialized physiological processes of motility, secretion, digestion, and
absorption, which further coordinStely interact with pancreatic and hepatobiliary functions. In addition, the
gastrointestinal system is subject to extensive paracrine, endocrine, and neurocrine regulatory mechanisms
that modulate its digestive functions, as well as innate and adaptive immunologic mechanisms that mediate
mucosal defense. Hence, increasing focus is aimed at elucidating molecular signaling events that mediate
alterations in regulatory genes and functional protein expression, and thereby exert such modulatory
influences on local physiological processes in the alimentary tract. In this context, recent developments in
gene expression and protein analysis technologies indicate that the molecular research tools available are
already sufficiently advanced to approach many questions relevant to normal and abnormal processes of
the digestive system, including cell signaling, integrative physiology, functional disorders, diseases and its
complications.
The Molecular Vector and Peptidomics Core is therefore intended to serve as a comprehensive resource
that will provide access to state-of-the-art molecular tools, and thereby aims to facilitate the research
activities of CURE: DDRCC investigators. This Core represents the consolidation of two previous Cores
(the Molecular Vector Core and the Peptidomics / RIA / Proteomics Core) into one integrated unit, intended
to maximize efficiency and ease of utilization, while minimizing overiap with other existing core facilities
already accessible on campus (see Fig. 1).
As such, this Core is now well-positioned to offer CURE: DDRCC investigators a wide variety of unique
research reagents and individually customized services, ranging from viral vector-mediated gene delivery to
functional protein analysis, which cannot be readily obtained from commercial or other academic sources at
comparable cost. By consolidating these services and expertise into a single integrated Core, we anticipate
that users will be provided with more efficient "one-stop shopping", as well as the flexibility to offer a variety
of molecular approaches that can be tailored to optimally meet the needs of individual research projects.
Gene delivery and protein expression technologies: Recent advances in vector technology have
made it feasible to utilize gene transfer as a methodology to elucidate the functions of specific genetic
sequences by examining the phenotypic consequences of their overexpression or inhibition of specific
proteins in transduced cells in vitro and in vivo; in this sense, gene transfer technology can be viewed as a
highly useful tool for functional genomics and proteomics.
In particular, viral vector technologies developed over the past two decades offer the advantages of
consistent and reliable gene transfer that, unlike physical or chemical transfection methods, can achieve
extremely high efficiencies. Depending on the vector system used, viral gene transfer can achieve longterm
expression of cDNAs encoding wild type or mutant proteins (e.g., constitutively active or dominantnegative),
as well as antisense and small hairpin RNA sequences, in large populations of quiescent primary
cells as well as immortalized cell lines, without the need for stable selection and hence without incurring the
risk of confounding clonal selection bias effects. Furthermore, stably integrating retroviral and especially
lentiviral gene transfer vectors can also be introduced directly into fertilized oocytes or embryonic
blastocysts to more efficiently generate transgenic animal models. If the effects of transgene expression in
conventional or vector-generated transgenic animals result in embryonic lethality, viral vectors can also be
used for post-natal gene transfer directly to somatic cells in target tissues.
Despite the advantages cited above, use of viral vector technology requires specialized expertise and
resources often not found in an individual investigator's laboratory. Easy access to these technologies can
therefore facilitate and expand the scope of research activities, and will provide a means for investigators to
rapidly generate preliminary data. Viral gene transfer technologies have now sufficiently matured and are
robust, reliable, and useful enough to warrant offering easy access to gene expression vectors through a
Core. Consolidation of these services as a Core is more cost-effective than utilizing commercially available
sources, and further value is added by customized technical support available from readily accessible and
knowledgeable staff who can work intensively with investigators to troubleshoot and optimize vector
applications. Thus, by providing such access to these technologies, we significantly facilitate the research
productivity of CURE: DDRCC investigators, and furthermore, we complement the existing strengths of
other CURE: DDRCC Research Cores, including the Animal Models Core and the Morphology and Cell
Imaging Core.
Quantitative and functional peptide / protein analysis technologies: Proteomics has established
itself as a highly valuable technology for studying complex biological problems and for the identification of
disease markers, but is methodologically restricted to the analysis of proteins with higher molecular masses
(>10 kDa). The development of a technology which covers peptides with low molecular weight and small
proteins (0.5 to 15 kDa) has been necessary, since peptides, amongst them families of hormones,
neuropeptides, cytokines and growth factors, play a central role in many biological processes, especially in
the regulation of the functions of the digestive system. In many cases, particulariy for smaller peptides,
direct synthesis is a simpler alternative to gene delivery-based protein expression, and for example, peptide
dose-response parameters in signal transduction can be more easily controlled with use of pre-synthesized
material. Improved isolation and detection technologies also permit more sensitive and quantitative
analysis of peptides and small proteins in complex mixtures and cell lysates. To summarize the
technologies used for this approach the term "peptidomics" is increasingly used. Recent developments in
peptidomics indicate that these technologies are also already sufficiently advanced to approach many
questions relevant to gastrointestinal physiology, diseases and its complications.
In response to these new and evolving technologies, services previously offered by the Peptidomics, RIA
and Proteomics Core, have been revised and refined, and consolidated with gene delivery and protein
expression technologies previously offered by the Molecular Vector Core. As such, the current
consolidated Molecular Vectors and Peptidomics Core now takes an integrated approach to the expression
and characterization of the whole spectrum of gene products from peptidomics to proteomics. This
integrated approach provides CURE: DDRCC investigators with a comprehensive breadth of molecular
tools to study digestive functions and diseases.
Most peptide- and protein-based services provided by the Core are performed on expensive instruments
that require high levels of expertise for operation and maintenance. This level of expense and expertise
cannot be duplicated in every CURE: DDRCC laboratory. Purification and purity analysis of synthetic
peptides obtained from vendors are performed on instruments that are best utilized in core facilities. The
cost of the instruments and the expertise for their optimal operation dictate their full time utilization by staff
working full time on these instruments. The other benefit to users is the peptide design expertise and
advisory service: investigators are not only provided with optimal peptide designs but also with detailed
explanations of the reasons for design features and presented with options to ensure that the best
candidate peptide is synthesized by commercial vendors in a cost-effective manner.
Additional services, including facilitated access to on-campus shared facilities specializing in proteomics,
and mass spectrometry, provide further benefit to CURE: DDRCC investigators. However, many such
experiments and projects require careful consultation between the CURE: DDRCC investigator and
knowledgeable Core staff, and frequently, resolution of obstacles can only be achieved after preliminary
experiments and in-depth discussion. The need for this type of critical interaction is not met when services
are sought from the commercial sector.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy
-
批准号:10443010
-
项目类别:
-
资助金额:$40.37万
-
财政年份:2019
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
-
批准号:9754592
-
项目类别:
-
资助金额:$51.15万
-
财政年份:2017
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
-
批准号:9384558
-
项目类别:
-
资助金额:$50.4万
-
财政年份:2017
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
-
批准号:10017020
-
项目类别:
-
资助金额:$53.03万
-
财政年份:2017
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Translational Development of Replication-Competent Retrovirus Vectors
-
批准号:8548414
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Translational Development of Replication-Competent Retrovirus Vectors
-
批准号:8077255
-
项目类别:
-
资助金额:$91.4万
-
财政年份:2010
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Translational Development of Replication-Competent Retrovirus Vectors
-
批准号:8322132
-
项目类别:
-
资助金额:$93.92万
-
财政年份:2010
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Translational Development of Replication-Competent Retrovirus Vectors
-
批准号:7826184
-
项目类别:
-
资助金额:$102.62万
-
财政年份:2010
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Vector Shared Resource
-
批准号:7944613
-
项目类别:
-
资助金额:$11.59万
-
财政年份:2009
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Cellular Transduction with Replication-Competent Retrovirus Vectors
-
批准号:7554139
-
项目类别:
-
资助金额:$48.19万
-
财政年份:2007
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Cellular Transduction with Replication-Competent Retrovirus Vectors
-
批准号:7746420
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2007
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Cellular Transduction with Replication-Competent Retrovirus Vectors
-
批准号:8017370
-
项目类别:
-
资助金额:$47.68万
-
财政年份:2007
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Cellular Transduction with Replication-Competent Retrovirus Vectors
-
批准号:7383097
-
项目类别:
-
资助金额:$46.79万
-
财政年份:2007
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Cellular Transduction with Replication-Competent Retrovirus Vectors
-
批准号:7261648
-
项目类别:
-
资助金额:$48.01万
-
财政年份:2007
-
负责人:NORIYUKI KASAHARA
-
依托单位:
CORE--MOLECULAR BIOLOGY AND VECTORS
-
批准号:7415065
-
项目类别:
-
资助金额:$5.73万
-
财政年份:2006
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Combining Virotherapy and Immunotherapy for Cancer
-
批准号:7005665
-
项目类别:
-
资助金额:$30.93万
-
财政年份:2004
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Combining Virotherapy and Immunotherapy for Cancer
-
批准号:7177498
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Combining Virotherapy and Immunotherapy for Cancer
-
批准号:6846599
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2004
-
负责人:NORIYUKI KASAHARA
-
依托单位:
CORE--MOLECULAR BIOLOGY AND VECTORS
-
批准号:6863977
-
项目类别:
-
资助金额:$5.9万
-
财政年份:2004
-
负责人:NORIYUKI KASAHARA
-
依托单位:
Combining Virotherapy and Immunotherapy for Cancer
-
批准号:7345428
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:NORIYUKI KASAHARA
-
依托单位:
海外基金